PRNewsWire
22 Jun 2026, 08:29 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging the company 'stuffed the channel' to artificially simulate sales activity. — Allegations of channel stuffing suggest fraudulent revenue inflation, which typically leads to severe valuation corrections and loss of investor trust.
-0.80The lawsuit against ADMA Biologics claims the company failed to disclose a related party transaction and made materially misleading public statements. — Lack of disclosure regarding related party transactions indicates potential governance failures and conflicts of interest.
-0.60The class period for the alleged securities law violations extends from August 9, 2024, to March 25, 2026. — The broad timeframe of the alleged misconduct increases the potential scale of financial damages and the number of affected shareholders.
-0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging securities law violations, false statements, and channel stuffing.
The company is named as the subject of a class action lawsuit for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
